The shareholders of medical technology company Monivent are called to an extraordinary general meeting, also serving as a second control meeting, on 15 October in Gothenburg.
At an extraordinary general meeting, also serving as the first control meeting, on 18 May, the shareholders resolved that the company’s operations should continue. Under the Swedish Companies Act, the company is required to hold a second control meeting within eight months, which is now taking place.
The board of directors primarily proposes that the meeting resolve that the company’s operations should continue.
Since the first control meeting, Monivent has carried out a directed issue of units and a directed set-off issue of units. The control balance sheet shows that the company’s equity has been fully restored, and the board therefore assesses that there is no capital deficiency.
As a secondary proposal, the board of directors proposes that the meeting resolve on liquidation. The reason is that, under the Swedish Companies Act, the board is also required to prepare a proposal for a resolution on liquidation to be submitted to the meeting.
